INDV
Indivior Pharmaceuticals Inc
$34.94
+0.11
(+0.32%)
Mkt Cap
4.36B
Volume
1,019,385
52W Range
22.22-42.81
Sector
Healthcare
Beta
1.11
EPS (TTM)
2.84 USD
P/E Ratio
12.30
Revenue (TTM)
1.33B USD
Rev Growth (5Y)
+13.9%
EPS Growth (5Y)
+25.3%
AlphaVal · Fair Value
What we estimate one share is worth
$25.39
Overvalued
moderate signal
37.6% above fair value
Modeled from cash flows & growth.
AlphaQuality · Grade · Gated
How strong & durable the business is
F
Stable Earnings Power
30.0 / 100 pillar composite (overridden)
Steady, predictable earnings power — graded A–F vs. similar companies.
Company Description
Indivior Pharmaceuticals Inc. operates as a holding company, primarily engaged in the research, production, and distribution of buprenorphine-based prescription medications designed to treat opioid dependence. Its product lineup features key pharmaceuticals such as Suboxone Film, Suboxone Tablet, and Subutex Tablet. The company organizes its business into several geographical regions: the United States, the United Kingdom, and the broader international market. Established on September 26, 2014, its corporate headquarters are located in North Chesterfield, Virginia.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.24B | 1.19B | 1.09B | 901.00M | 791.00M | 647.00M | 785.00M | 959.92M | 1.15B | 968.89M |
| Net Income | 210.00M | 2.00M | (129.00M) | (44.00M) | 205.00M | (148.00M) | 134.00M | 262.67M | 60.92M | 32.05M |
| EPS | 1.68 | 0.02 | -0.94 | -0.37 | 1.38 | -1.08 | 0.95 | 1.81 | 0.42 | 0.22 |
| Free Cash Flow | (94.00M) | 5.00M | (353.00M) | (9.00M) | 319.00M | (197.00M) | 144.00M | 262.00M | 252.00M | 372.00M |
| FCF / Share | -0.75 | 0.04 | -2.57 | -0.06 | 2.19 | -1.34 | 0.99 | 1.80 | 1.75 | 2.58 |
| Operating CF | (27.00M) | 36.00M | (300.00M) | (4.00M) | 353.00M | (193.00M) | 151.00M | 303.00M | 295.00M | 407.00M |
| Total Assets | 1.20B | 1.32B | 1.76B | 1.78B | 1.83B | 1.53B | 1.65B | 1.55B | 1.44B | 1.21B |
| Total Debt | 351.00M | 375.00M | 283.00M | 277.00M | 286.00M | 285.00M | 293.00M | 241.00M | 482.00M | 535.00M |
| Cash & Equiv | 195.00M | 319.00M | 316.00M | 778.18M | 1.10B | 858.00M | 1.06B | 924.00M | 863.00M | 692.00M |
| Book Value | (98.00M) | (348.00M) | (191.00M) | 51.28M | 203.00M | 82.00M | 209.00M | 66.00M | (203.00M) | (295.00M) |
| Return on Equity | N/A | N/A | N/A | -0.86 | 1.01 | -1.80 | 0.64 | 3.98 | N/A | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 343.00M | 317.00M | 358.00M | 314.00M | 302.00M | 266.00M | 299.00M | 307.00M | 299.00M | 284.00M | 293.00M | 271.00M |
| Net Income | 122.00M | 89.00M | 102.00M | 42.00M | 18.00M | 47.00M | 59.00M | 4.00M | (97.00M) | 61.00M | 54.00M | (135.00M) |
| EPS | 0.97 | 0.71 | 0.82 | 0.34 | 0.14 | 0.38 | 0.45 | 0.03 | -0.72 | 0.45 | 0.39 | -0.94 |
| Free Cash Flow | 222.00M | (29.00M) | (245.00M) | (59.00M) | 140.00M | 70.00M | (21.00M) | (5.00M) | 84.00M | (40.00M) | (299.00M) | (7.00M) |
| FCF / Share | 1.77 | -0.23 | -1.96 | -0.47 | 1.13 | 0.57 | -0.17 | -0.04 | 0.62 | -0.29 | -2.18 | -0.05 |
| Operating CF | 229.00M | (9.00M) | (221.00M) | (39.00M) | 158.00M | 75.00M | (5.00M) | 2.00M | 88.00M | (37.00M) | (281.00M) | 21.00M |
| Total Assets | 1.23B | 1.20B | 1.20B | 1.42B | 1.45B | 1.38B | 1.32B | 1.46B | 1.54B | 1.45B | 1.76B | 1.85B |
| Total Debt | 509.00M | 509.00M | 351.00M | 356.00M | 366.00M | 370.00M | 375.00M | 284.00M | 281.04M | 278.79M | 283.00M | 277.00M |
| Cash & Equiv | 222.00M | 175.00M | 195.00M | 445.00M | 510.00M | 372.00M | 319.00M | 288.00M | 302.05M | 247.81M | 316.00M | 610.00M |
| Book Value | (208.00M) | (144.00M) | (98.00M) | (207.00M) | (258.00M) | (286.00M) | (348.00M) | (167.00M) | (121.02M) | 9.99M | (191.00M) | (24.00M) |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 6.10 | N/A | N/A |
INDV News
INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV)
Supernus Pharmaceuticals (SUPN) Announces Transformative Merger with Indivior (INDV)
Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Revenue